RT Journal Article
SR Electronic
T1 ILK Expression in Colorectal Cancer Is Associated with EMT, Cancer Stem Cell Markers and Chemoresistance
JF Cancer Genomics - Proteomics
JO Cancer Genomics Proteomics
FD International Institute of Anticancer Research
SP 127
OP 141
VO 15
IS 2
A1 TSOUMAS, DIMITRIOS
A1 NIKOU, SOFIA
A1 GIANNOPOULOU, EFSTATHIA
A1 TSANIRAS, SPYRIDON CHAMPERIS
A1 SIRINIAN, CHAIDO
A1 MAROULIS, IOANNIS
A1 TARAVIRAS, STAVROS
A1 ZOLOTA, VASSILIKI
A1 KALOFONOS, HARALABOS P.
A1 BRAVOU, VASILIKI
YR 2018
UL http://cgp.iiarjournals.org/content/15/2/127.abstract
AB Background/Aim: Epithelial-mesenchymal transition (EMT) and cancer stem cells (CSC) are critically implicated in cancer metastasis and chemoresistance. Herein, we investigated integrin-linked kinase (ILK)'s role in human colon cancer (CRC) progression and chemoresistance in relation to EMT and CSC markers. Patients and Methods: Expression of ILK, EMT and CSC markers were evaluated by immunohistochemistry in 149 CRC samples. We also generated colon cancer cells resistant to 5-FU and oxaliplatin and studied the effect of ILK inhibition on drug response by MTT assay and on EMT and CSC markers' expression. Results: ILK expression in human CRC correlates with EMT and CSC markers and is associated with metastasis and chemoresistance. ILK inhibition increases sensitivity of resistant cells to 5-FU and oxaliplatin and reduces the levels of EMT and CSC markers in 5-FU resistant cells. Conclusion: ILK overexpression in human CRC associates with EMT and CSC traits, contributing to tumor progression and chemoresistance.